ATE478658T1 - Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung - Google Patents
Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichungInfo
- Publication number
- ATE478658T1 ATE478658T1 AT05819409T AT05819409T ATE478658T1 AT E478658 T1 ATE478658 T1 AT E478658T1 AT 05819409 T AT05819409 T AT 05819409T AT 05819409 T AT05819409 T AT 05819409T AT E478658 T1 ATE478658 T1 AT E478658T1
- Authority
- AT
- Austria
- Prior art keywords
- oral administration
- solid
- prevent abuse
- solid medicinal
- prevent
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940126701 oral medication Drugs 0.000 abstract 1
- 230000005180 public health Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0412428A FR2878161B1 (fr) | 2004-11-23 | 2004-11-23 | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
| PCT/FR2005/050969 WO2006056712A1 (fr) | 2004-11-23 | 2005-11-21 | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE478658T1 true ATE478658T1 (de) | 2010-09-15 |
Family
ID=34953543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05819409T ATE478658T1 (de) | 2004-11-23 | 2005-11-21 | Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080193540A1 (de) |
| EP (1) | EP1814523B9 (de) |
| JP (1) | JP5038146B2 (de) |
| CN (1) | CN101094654A (de) |
| AT (1) | ATE478658T1 (de) |
| CA (1) | CA2589160A1 (de) |
| DE (1) | DE602005023203D1 (de) |
| ES (1) | ES2350589T3 (de) |
| FR (1) | FR2878161B1 (de) |
| WO (1) | WO2006056712A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| CA2480826C (fr) | 2002-04-09 | 2012-02-07 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
| US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
| FR2881652B1 (fr) * | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
| WO2006133733A1 (en) | 2005-06-13 | 2006-12-21 | Flamel Technologies | Oral dosage form comprising an antimisuse system |
| FR2892937B1 (fr) * | 2005-11-10 | 2013-04-05 | Flamel Tech Sa | Forme pharmaceutique orale microparticulaire anti-mesusage |
| US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| SG185296A1 (en) * | 2007-10-12 | 2012-11-29 | Takeda Pharmaceuticals Usa Inc | Methods of treating gastrointestinal disorders independent of the intake of food |
| ES2414856T3 (es) * | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Formulaciones de fármaco narcótico con potencial de adicción disminuido |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ597283A (en) | 2009-06-24 | 2013-07-26 | Egalet Ltd | Controlled release formulations |
| FR2960775A1 (fr) * | 2010-06-07 | 2011-12-09 | Ethypharm Sa | Microgranules resistants au detournement |
| BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| WO2016057517A1 (en) * | 2014-10-07 | 2016-04-14 | Therakine | Micronized delivery material, method for manufacturing thereof and methods for application |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2530563C2 (de) * | 1975-07-09 | 1986-07-24 | Bayer Ag, 5090 Leverkusen | Analgetische Arzneimittel mit vermindertem Mißbrauchspotential |
| EP0198769A3 (de) * | 1985-04-12 | 1987-09-02 | Forest Laboratories, Inc. | Schwimmfähige therapeutische Mittel mit verzögerter Freisetzung |
| GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| US6444246B1 (en) * | 1997-12-16 | 2002-09-03 | Mccormick & Company, Inc. | Cake-resistant, hygroscopically sensitive materials and process for producing the same |
| US20020068365A1 (en) * | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6566560B2 (en) * | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| AU6786001A (en) * | 2000-07-05 | 2002-01-14 | Asahi Chemical Ind | Cellulose powder |
| DE20220917U1 (de) * | 2001-08-06 | 2004-08-19 | Euro-Celtique S.A. | Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden |
| JP4694207B2 (ja) * | 2002-07-05 | 2011-06-08 | コルジウム ファーマシューティカル, インコーポレイテッド | オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 |
| US20040208936A1 (en) * | 2002-07-22 | 2004-10-21 | Roland Chorin | Novel compositions |
| ATE482695T1 (de) * | 2002-12-13 | 2010-10-15 | Durect Corp | Orale darreichungsform mit flüssigen hochviskosen trägersystemen |
| US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
| NZ545202A (en) * | 2003-08-06 | 2010-03-26 | Gruenenthal Chemie | Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
-
2004
- 2004-11-23 FR FR0412428A patent/FR2878161B1/fr not_active Expired - Fee Related
-
2005
- 2005-11-21 DE DE602005023203T patent/DE602005023203D1/de not_active Expired - Lifetime
- 2005-11-21 ES ES05819409T patent/ES2350589T3/es not_active Expired - Lifetime
- 2005-11-21 CN CNA2005800458625A patent/CN101094654A/zh active Pending
- 2005-11-21 WO PCT/FR2005/050969 patent/WO2006056712A1/fr not_active Ceased
- 2005-11-21 EP EP05819409A patent/EP1814523B9/de not_active Expired - Lifetime
- 2005-11-21 US US11/791,336 patent/US20080193540A1/en not_active Abandoned
- 2005-11-21 JP JP2007542065A patent/JP5038146B2/ja not_active Expired - Fee Related
- 2005-11-21 CA CA002589160A patent/CA2589160A1/fr not_active Abandoned
- 2005-11-21 AT AT05819409T patent/ATE478658T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080193540A1 (en) | 2008-08-14 |
| CA2589160A1 (fr) | 2006-06-01 |
| EP1814523B9 (de) | 2011-01-12 |
| JP2008520634A (ja) | 2008-06-19 |
| EP1814523A1 (de) | 2007-08-08 |
| DE602005023203D1 (de) | 2010-10-07 |
| CN101094654A (zh) | 2007-12-26 |
| FR2878161B1 (fr) | 2008-10-31 |
| ES2350589T3 (es) | 2011-01-25 |
| WO2006056712A1 (fr) | 2006-06-01 |
| FR2878161A1 (fr) | 2006-05-26 |
| JP5038146B2 (ja) | 2012-10-03 |
| EP1814523B1 (de) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE478658T1 (de) | Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung | |
| WO2006089843A3 (fr) | Forme medicamenteuse orale microparticulaire anti-mesusage | |
| EA200600696A1 (ru) | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств | |
| WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
| Henningfield et al. | Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy | |
| TW200630093A (en) | Dose forms | |
| WO2008085765A3 (en) | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain | |
| NO20064041L (no) | Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter | |
| ATE553750T1 (de) | Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch | |
| BRPI0520082A2 (pt) | formas de dosagem de risedronato | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| ATE413162T1 (de) | Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln | |
| WO2007149406A3 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| JP2010503695A5 (de) | ||
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| WO2007084424A3 (en) | Treatment of substance abuse | |
| CY1112184T1 (el) | Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| WO2008106689A3 (en) | Breakthrough pain management | |
| DK1656131T3 (da) | Anvendelse af betain til behandling claudicatio intermittens | |
| DE502006007702D1 (de) | Tablettenförmige retardzubereitung enthaltend cinnarizin und dimenhydrinat gegen schwindel | |
| WO2005082413A3 (en) | Ciclesonide and glycopyrronium combination | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |